Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG, Cyclosporine, and MMF for Severe Aplastic Anemia
NCT00001964Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Mar 2000
- Primary completion
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mycophenolate mofetil in aplastic anemia, sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Reduction in 24-month relapse. Started Mar 2000; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT00001964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001964.